<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232726</url>
  </required_header>
  <id_info>
    <org_study_id>CP4055-201</org_study_id>
    <nct_id>NCT00232726</nct_id>
  </id_info>
  <brief_title>Clinical Study of Previously Untreated Patients With Malignant Melanoma</brief_title>
  <official_title>A Non-Randomised, Multicentre, Phase II Clinical Study of CP-4055 in Chemotherapy-Naïve Patients With Metastatic Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clavis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clavis Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previously untreated patients with malignant melanoma receive a new chemotherapy drug&#xD;
      currently under development. CP-4055 is given intravenously on days 1-5 every four weeks&#xD;
      until complete response or disease progression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international multicentre phase II clinical study conducted in the USA and Europe.&#xD;
      Previously untreated patients over 18 years, with metastatic malignant melanoma are eligible&#xD;
      for inclusion if they fulfil all inclusion- and exclusion criteria. 16 or 42 patients will be&#xD;
      enrolled in Pittsburgh USA, Lund Sweden and Oslo Norway.&#xD;
&#xD;
      The new development drug CP-4055 is administered for five consecutive days (Day 1 to 5) in a&#xD;
      4 week schedule (one cycle). The dose is 200 mg/m2/day.&#xD;
&#xD;
      A patient will continue treatment until complete response or until (s)he is withdrawn from&#xD;
      the Clinical Study because of disease progression, unacceptable toxicity or any other reason&#xD;
      described in the clinical study protocol.&#xD;
&#xD;
      Efficacy is assessed at baseline and end of every second cycle with CT or MRI.&#xD;
&#xD;
      Safety assessments are done at each visit. Blood samples are taken and haematological and&#xD;
      biochemical parameters are assessed for safety.&#xD;
&#xD;
      Any adverse events are recorded and reported.&#xD;
&#xD;
      The clinical study has been approved by the relevant Independent Ethical&#xD;
      Committees/Institutional Review Boards and Concerned Regulatory Authority as appropriate. It&#xD;
      is conducted according to ICH Good Clinical Practice, the Declaration of Helsinki, and&#xD;
      applicable national law and regulations.&#xD;
&#xD;
      Patients who give an additional consent will have two additional, and not mandatory,&#xD;
      procedures performed:&#xD;
&#xD;
        -  Biopsy (tissue sample) from particular tumours (taken only at baseline for&#xD;
           identification of tumour genes)&#xD;
&#xD;
        -  Serum samples (from blood drawn at baseline and at end of the cycle 2 for protein&#xD;
           sequences analyses, proteomics)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumour response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of tumour response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Malignant Melanoma</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-4055 (ELACYT)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed stage IV or unresectable stage&#xD;
             III non-ocular malignant melanoma who have not undergone prior chemotherapy for the&#xD;
             treatment of melanoma (chemotherapy-naïve)&#xD;
&#xD;
          -  Measurable disease according to Response Criteria in Solid Tumours (RECIST)&#xD;
&#xD;
          -  Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group)&#xD;
             Performance Status&#xD;
&#xD;
          -  Age 18 years or more&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Adequate haematological and biological functions:&#xD;
&#xD;
               -  Bone marrow function:&#xD;
&#xD;
                    1. Neutrophils ≥ 1.5 x 10^9/L&#xD;
&#xD;
                    2. Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
                    3. Hemoglobin (Hb) ≥ 10 g/dL&#xD;
&#xD;
               -  Hepatic function:&#xD;
&#xD;
                    1. AST/ALT ≤ 2.5 times institutional upper limit of normal (ULN). If liver&#xD;
                       metastases, ≤ 5 times institutional ULN.&#xD;
&#xD;
                    2. Serum bilirubin and alkaline phosphatase ≤ 1.5 times institutional ULN&#xD;
&#xD;
               -  Renal function:&#xD;
&#xD;
                    -  Creatinine ≤ 1.5 times institutional ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known brain metastases&#xD;
&#xD;
          -  Diagnosis of ocular malignant melanoma&#xD;
&#xD;
          -  Radiotherapy to more than 30% of bone marrow&#xD;
&#xD;
          -  Participation in another therapeutic clinical study within 30 days of enrolment or&#xD;
             during this clinical study&#xD;
&#xD;
          -  Prior immunotherapy and/or chemotherapy for the treatment of melanoma&#xD;
&#xD;
          -  Requirement of concomitant treatment with a non-permitted medication:&#xD;
&#xD;
               -  Alternative drugs&#xD;
&#xD;
               -  High doses of vitamins&#xD;
&#xD;
          -  History of allergic reactions to Ara-C or egg&#xD;
&#xD;
          -  Presence of any serious concomitant systemic disorders incompatible with the clinical&#xD;
             study (e.g. uncontrolled intercurrent illness including ongoing or active infection)&#xD;
&#xD;
          -  Presence of any significant central nervous system or psychiatric disorder(s) that&#xD;
             would hamper the patient's compliance&#xD;
&#xD;
          -  Pregnancy, breastfeeding, or absence of adequate contraception for both male and&#xD;
             female fertile patients&#xD;
&#xD;
          -  Known positive status for HIV and/or hepatitis B or C&#xD;
&#xD;
          -  Drug and/or alcohol abuse&#xD;
&#xD;
          -  Any reason why, in the Investigator's opinion, the patient should not participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svein Dueland, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Norwegian Radium Hospital, Montebello, NO-0310 Oslo, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clavispharma.com</url>
    <description>Sponsor's home page</description>
  </link>
  <verification_date>July 2007</verification_date>
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <last_update_submitted>July 9, 2007</last_update_submitted>
  <last_update_submitted_qc>July 9, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2007</last_update_posted>
  <keyword>Malignant melanoma</keyword>
  <keyword>CP-4055</keyword>
  <keyword>Chemotherapy-naïve patients</keyword>
  <keyword>Phase II</keyword>
  <keyword>Chemotherapy-naive patients</keyword>
  <keyword>Metastatic malignant melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

